Expertise in
15
conditions

Dr. Brian C. Baumann

Radiation Oncology
Springfield Clinic, Llp
1025 S 6th St, 
Springfield, IL 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Expertise in
15
conditions
Springfield Clinic, Llp
1025 S 6th St, 
Springfield, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Baumann is a Radiation Oncologist in Springfield, Illinois. Dr. Baumann is highly rated in 15 conditions, according to our data. His top areas of expertise are Prostate Cancer, Adult Soft Tissue Sarcoma, Familial Prostate Cancer, and Angiosarcoma of the Scalp. Dr. Baumann is currently accepting new patients.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Barnes Jewish Hospital
St Johns Hospital
Memorial Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

SPRINGFIELD CLINIC, LLP
1025 S 6th St, Springfield, IL 62703
Other Locations
SPRINGFIELD CLINIC, LLP
567 N Westgate Ave, Jacksonville, IL 62650
SPRINGFIELD CLINIC, LLP
2200 Wabash Ave, Springfield, IL 62704
SPRINGFIELD CLINIC, LLP
900 N 1st St, Springfield, IL 62702
SPRINGFIELD CLINIC, LLP
701 N 1st St, Springfield, IL 62781
SPRINGFIELD CLINIC, LLP
775 Engineering Ave, Springfield, IL 62703
SPRINGFIELD CLINIC, LLP
301 N 8th St, Springfield, IL 62701
SPRINGFIELD CLINIC, LLP
1000 W Morton Ave, Jacksonville, IL 62650
SPRINGFIELD CLINIC, LLP
100 Stahlhut Dr, Lincoln, IL 62656
SPRINGFIELD CLINIC, LLP
400 Saint Johns Dr, Sherman, IL 62684
SPRINGFIELD CLINIC, LLP
600 N Main St, Taylorville, IL 62568

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Enrollment Status: Recruiting
Publish Date: March 25, 2025
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Enrollment Status: Recruiting
Publish Date: December 06, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

113 Total Publications

Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology.
Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology.
Journal: Practical radiation oncology
Published: April 01, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Parashar J. Nanavati
Radiation Oncology
Expertise in
10
conditions
Dr. Parashar J. Nanavati
Radiation Oncology

Springfield Clinic, Llp

775 Engineering Ave, 
Springfield, IL 
 (2.2 miles away)
217-522-4300
Languages Spoken:
English
See accepted insurances

Parashar Nanavati is a Radiation Oncologist in Springfield, Illinois. Dr. Nanavati is highly rated in 10 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Vulvar Cancer, and Pleuropulmonary Blastoma.

Expertise in
20
conditions
Dr. Harold A. Yoon
Radiation Oncology
Expertise in
20
conditions
Dr. Harold A. Yoon
Radiation Oncology

Cancer Care Specialists Of Central Illinois Sc

210 W Mckinley Ave, Suite 1, 
Decatur, IL 
 (37.0 miles away)
217-877-9442
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harold Yoon is a Radiation Oncologist in Decatur, Illinois. Dr. Yoon is highly rated in 20 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Small Cell Lung Cancer (SCLC), Prostate Cancer, and Lung Cancer. Dr. Yoon is currently accepting new patients.

Expertise in
9
conditions
Dr. Saleem Mahmood
Radiation Oncology
Expertise in
9
conditions
Dr. Saleem Mahmood
Radiation Oncology

St Johns Hospital Of The Hospital Sisters Of The Third Order Of St F

800 E Carpenter St, 
Springfield, IL 
 (1.1 miles away)
217-544-6464
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Saleem Mahmood is a Radiation Oncologist in Springfield, Illinois. Dr. Mahmood is highly rated in 9 conditions, according to our data. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Lung Adenocarcinoma. Dr. Mahmood is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baumann's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile